Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06860802 · ClinicalTrials.gov registry record · Phase 1
Precision Antibiotic Dosing for Appendectomy
A Phase 1 study of Appendicitis (Diagnosis), sponsored by University of Michigan.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 46
- Enrollment target
- 1
- Study location
NCT06860802 is a Phase 1 study of Appendicitis (Diagnosis) that is actively recruiting participants, run by University of Michigan. The registered enrollment target is 46 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06860802, a Phase 1 study of Appendicitis (Diagnosis), is actively recruiting participants, sponsored by University of Michigan.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 46 participants
- Enrollment target
- 1
- Study location
Study Summary
This research is studying a drug called cefoxitin already approved by the Food and Drug Administration (FDA) to reduce the risk of infection after surgery to remove an appendix. Researchers are studying a large group of people to continue to learn how best to dose antibiotics. This research will compare the current standard treatment which is a single dose prior to surgery to a new method that includes adding another dose of cefoxitin within 30 minutes of starting the surgery. This study will measure cefoxitin concentrations in blood, fat, and appendix tissue samples to compare the standard dosing method to our new method. This information will help us figure out the right dose of this drug to prevent infection after surgery to remove an appendix.
Conditions Studied
Interventions
- DRUG Cefoxitin
Study Locations (1)
Michigan
- Michigan Medicine - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2025-02-28 |
| Est. Completion | 2026-09-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06860802
The ClinicalTrials.gov registry entry for NCT06860802 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Michigan, which has 1,327 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Appendicitis (Diagnosis) appearing as the primary indexed condition, and to 1 intervention - of which Cefoxitin is the first listed.
NCT06860802 reports 1 study location spanning 1 distinct geographic area - top geographies include Michigan.
Frequently Asked Questions
What is clinical trial NCT06860802 about?
NCT06860802 is a clinical study titled "Precision Antibiotic Dosing for Appendectomy". This research is studying a drug called cefoxitin already approved by the Food and Drug Administration (FDA) to reduce the risk of infection after surgery to remove an appendix. Researchers are studying a large group of people to continue to learn how best to dose antibiotics. This research will com...
What is the current status of trial NCT06860802?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 46 participants. The study started on 2025-02-28. Estimated completion is 2026-09-30.
What conditions does trial NCT06860802 study?
This clinical trial studies the following conditions: Appendicitis (Diagnosis).
What interventions are being tested in trial NCT06860802?
The interventions under investigation include: Cefoxitin (DRUG).
Who is sponsoring clinical trial NCT06860802?
This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06860802 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.